Clinical trial
Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
NCT00404495 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00404495 |
|---|---|
| Title | Combination of Irinotecan and Temozolomide in Children With Brain Tumors. |
| Official title | Phase 2 Single-Arm, Open Label Study Of Irinotecan In Combination With Temozolomide In Children With Recurrent Or Refractory Medulloblastoma And In Children With Newly Diagnosed High-Grade Glioma. |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioma, Medulloblastoma |
| Intervention type | Drug |
| Interventions | Irinotecan, Temozolomide |
| Enrollment | 83 |
| Start date | Apr 1, 2007 |
| Primary completion | Jan 1, 2011 |
| Completion | Dec 1, 2011 |
| First posted | Nov 28, 2006 |
| Last update posted | Apr 18, 2012 |
| Countries | Australia, Belgium, Denmark, France, Italy, Poland, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: